Instructions for Euphylline (Aminophylline)
English product name
Euphylline
Release form
tab. 150 mg: 10, 15, 20, 30, 40, 45, 50, 60, 75 or 100 pcs
Description
Tablets 1 tab.
aminophylline 150 mg
ATC codes
R03DA05 Aminophylline
Clinical-pharmacological groups / Group affiliation
Broncholytic preparation - phosphodiesterase inhibitor
Active substance
aminophylline
Pharmacotherapy group:
Bronchodilating agent - phosphodiesterase inhibitor
Pharmacological effect Euphylline
Broncholytic agent, PDE inhibitor. It is the ethylenediamine salt of theophylline (which facilitates solubility and increases absorption). It has bronchial augmentation, apparently caused by a direct relaxing effect on the smooth muscles of the airways and blood vessels of the lungs. This action is thought to be caused by selective suppression of specific PDEs, leading to an increase in intracellular concentration of cAMP. Experimental results from in vitro show that type III and type IV isoenzymes seem to play a major role. The suppression of the activity of these isoenzymes can also cause some side effects of aminophylline (theophylline), including vomiting, arterial hypotension and tachycardia. It blocks adenosine (purine) receptors, which may be a factor in bronchi activity.
Reduces respiratory tract hyperreactivity associated with late-stage allergen inhalation reactions through an unknown mechanism that is not related to PDE inhibition or adenosine blockade. There are reports that aminophylline increases the number and activity of T suppressors in peripheral blood.
It promotes mucociliary clearance, stimulates diaphragm reduction, improves the function of the respiratory and intercostal muscles, stimulates the respiratory center, increases its sensitivity to carbon dioxide and improves alveolar ventilation, ultimately leading to a decrease in the severity and frequency of episodes of apnea. By normalizing the respiratory function, it contributes to the oxygen saturation of the blood and the reduction of the concentration of carbon dioxide. Increases lung ventilation in hypokalemia conditions.
Testimony Euphylline
For parenteral use: asthmatic status (additional therapy), newborn apnea, ischemic type cerebral circulation disorder (in combination therapy), left-ventricular insufficiency with bronchospasm and Cheyne-Stokes type breathing disorder, renal syndrome (in complex therapy); acute and chronic heart failure (as part of combination therapy).
To receive inside: Bronchosoobstructive syndrome of various origins (including bronchial asthma, COPD including pulmonary emphysema, chronic obstructive bronchitis), hypertension in the small circulatory circle, pulmonary heart, night apnea; acute and chronic heart failure (as part of combination therapy).
Method of use, course and dosage Euphylline
Individual, depending on indications, age, clinical situation, route and pattern of administration, nicotine dependence.
Application in elderly patients Aminophylline
With caution: elderly patients (dose reduction may be required).
Use in children
Contraindication: Children's age (up to 3 years, for prolonged oral forms - up to 12 years). Do not apply rectally in children.
- Nosology Euphylline (ICD codes)
- G47.3
- Sleep apnea (respiratory center disorders)
- I27.0
- Primary pulmonary hypertension
- I27.2
- Other secondary pulmonary hypertension
- I27.8
- Other refined forms of pulmonary heart failure
- I27.9
- Pulmonary heart failure unspecified (including pulmonary heart [cor pulmonale] (chronic) BDU)
- I50.0
- Congestive heart failure
- I50.1
- Left ventricular failure
- I63
- Brain infarction
- J43
- Emphysema
- J44
- Other chronic obstructive pulmonary disease
- J45
- Asthma
- J46
- Asthmatic status [status asthmaticus]
- N04
- Nephrotic syndrome
- P28.3
- Primary apnea during sleep in a newborn
- P28.4
- Other types of apnea in a newborn
